Online inquiry

IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4481MR)

This product GTTS-WQ4481MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD28 gene. The antibody can be applied in Lupus nephritis, Inflammatory diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001243077.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 940
UniProt ID P10747
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4481MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6929MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ3148MR IVTScrip™ mRNA-Anti-C3&C4, APT070(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA APT070
GTTS-WQ13513MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ14725MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ10306MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ10650MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ12775MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ14193MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-910
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW